Showing results (2881-2890 of 6,780) with videos related to
Sort By:
Pageof 678
Clinical Therapeutics|December 26, 2008
The economics of pediatric formulation development for off-patent drugsChristopher-Paul Milne, Jon B BrussClinical Therapeutics|November 19, 2008
Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group studyDavid E Martin, Hal Galbraith, Jared Schettler, et al.Clinical Therapeutics|November 19, 2008
Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteersBashar A Alkhalidi, Jaafar J Tamimi, Isam I Salem, et al.Clinical Therapeutics|November 19, 2008
Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trialsKleoniki G Kyriakidou, Petros Rafailidis, Dimitris K Matthaiou, et al.Clinical Therapeutics|November 19, 2008
Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trialOrapan Poachanukoon, Maleewan KitcharoensakkulClinical Therapeutics|November 19, 2008
In vitro stability of enoxaparin solutions (20 mg/mL) diluted in 4% glucoseRahul P Patel, Christian Narkowicz, Glenn A JacobsonClinical Therapeutics|November 19, 2008
Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipientsChelim Cheong, Jamie C Barner, Kenneth A Lawson, et al.Clinical Therapeutics|November 19, 2008
A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured populationHoward Friedman, Teresa Wilcox, Gregory Reardon, et al.Clinical Therapeutics|November 25, 2010
Safety profile of abatacept in rheumatoid arthritis: a reviewMajed Khraishi, Anthony Russell, Wojciech P OlszynskiClinical Therapeutics|November 25, 2010
Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteersJohn Davis, Frances Hackman, Marie-Noella Ndongo, et al.Pageof 678